Effects of pro-inflammatory cytokines on chondrogenesis of equine mesenchymal stromal cells derived from bone marrow or synovial fluid.
Authors: Zayed M N, Schumacher J, Misk N, Dhar M S
Journal: Veterinary journal (London, England : 1997)
Summary
# Editorial Summary Mesenchymal stromal cells (MSCs) show considerable promise for treating equine articular cartilage defects through chondrogenic differentiation, yet their therapeutic potential may be compromised when implanted into the inflammatory microenvironment characteristic of osteoarthritis. Zayed and colleagues investigated how pro-inflammatory cytokines—specifically interferon-gamma and tumour necrosis factor-alpha at clinically relevant concentrations—affect the chondrogenic capacity of MSCs sourced from either bone marrow or synovial fluid during standard TGF-β1-mediated differentiation protocols. Whilst both cell populations remained viable under inflammatory stimulation, glycosaminoglycan production decreased significantly in both sources, with bone marrow-derived MSCs showing broader suppression of chondrogenic markers (SOX-9, TGF-β1, aggrecan and collagen II) compared to synovial fluid-derived MSCs, which demonstrated selective reduction in aggrecan alone. These findings underscore a critical distinction between MSC survival and functional differentiation capacity: practitioners considering intra-articular MSC therapy should appreciate that inflammatory joint conditions may impair the ability of implanted cells to generate cartilage matrix components, despite the cells remaining metabolically active. The differential response between tissue sources suggests that synovial-derived MSCs may retain superior chondrogenic resilience in inflammatory settings, warranting consideration during cell source selection for regenerative cartilage applications.
Read the full abstract on PubMed
Practical Takeaways
- •Intra-articular MSC therapy may have reduced efficacy in inflamed joints typical of osteoarthritis, as the inflammatory environment inhibits the cells' ability to differentiate into cartilage-producing chondrocytes
- •Synovial fluid-derived MSCs appear more resistant to inflammatory inhibition than bone marrow-derived MSCs, suggesting source selection may be important for arthritis cases
- •Anti-inflammatory management alongside MSC therapy may be necessary to optimize chondrogenic differentiation and cartilage repair outcomes
Key Findings
- •Pro-inflammatory cytokines (IFN-γ 100 ng/mL and TNF-α 10 ng/mL) did not affect MSC viability but significantly decreased glycosaminoglycan production in both bone marrow and synovial fluid-derived MSCs
- •Bone marrow-derived MSCs showed reduced expression of SOX-9, TGF-β1, aggrecan and collagen II when exposed to pro-inflammatory cytokines
- •Synovial fluid-derived MSCs showed selective inhibition with only aggrecan expression reduced by pro-inflammatory cytokine exposure
- •Pro-inflammatory cytokines inhibit chondrogenic differentiation of equine MSCs without compromising cell proliferation